AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02772341 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Salt room without halogenerator
Description: Patients were assigned to 14 sessions (7 weeks, twice weekly, 45 minutes each treatment) sitting in a salt room without salt aerosol (placebo). Both the walls and the ceiling of the salt room are completely covered with ESCO-(European Salt Company) type certified-origin rock salt. The temperature (20-24°C) and humidity (44-60%) are at constant values.
Study NCT02244385 — intervention group
Intervention type: OTHER
Intervention: no intervention
Study NCT03181828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetohydroxamic Acid Oral Tablet
Description: A single oral dose of 60 mg/kg acetohydroxamic acid rounded to the nearest 250 mg tablet.
Study NCT02865616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MET-2
Description: Microbial Ecosystem Therapeutics (MET) is a new treatment approach for debilitating recurrent Clostridium difficile infection that has been developed as an alternative to fecal transplantation.
Study NCT02865616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Patients will be on vancomycin to control symptoms up until the time of the treatment. Patient must hold their p.o. vancomycin for 24 hours prior to receiving the first dose.
Study NCT02945501 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroConn DC Stimulator PLUS
Description: Prior to bedtime on the sleep restriction night, 4 transcranial stimulation electrodes (two on each hemisphere) will be applied to the scalps of each subject. Subjects will receive a one hour period of SO stimulation, for a total of approximately two hours of sleep.
Study NCT02945501 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM TES
Description: Prior to bedtime on the sleep restriction night, 4 placebo transcranial stimulation electrodes (two on each hemisphere) will be applied to the scalps of each subject. Subjects will sleep for approximately 2 hours without stimulation.
Study NCT02119858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green solution
Description: Given transperineally
Study NCT02119858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diffuse optical imaging
Description: Undergo near infrared fluorescence imaging
Study NCT02119858 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robot-assisted laparoscopic surgery
Description: Undergo robot-assisted laparoscopic radical prostatectomy
Study NCT02119858 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic lymphadenectomy
Description: Undergo lymphadenectomy
Study NCT03341559 — intervention group
Intervention type: DEVICE
Intervention: Spatial Frequency Domain Imaging (SFDI)
Description: Observational study to measure perfusion in lower extremities for prediction of both healing and formation of diabetic foot ulcers using Reflect RS
Study NCT03181828 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No treatment
Description: No treatment
Study NCT04434612 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OXSIGHT smart glasses
Description: OXSIGHT smart glasses are head-mounted electronic LVAs designed for LV patients with visual field loss.
Study NCT00958659 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00401414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: 2 mg tablets take as directed by study staff (based on INR)
Study NCT00632866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine : 200mg / day since 24 weeks
Study NCT00632866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo : 2cp/ day since 24 weeks
Study NCT04438980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: -A dose of 120 mg/day of methylprednisolone for 3 days, administered by intravenous infusión
Study NCT04438980 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: -An infusion bag of 100 mL of 0.9% saline
Study NCT03052751 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered in period 1 of dosage regimen 2.
Study NCT02199964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin 0.05% emulsion
Description: Topical therapy for dry eye
Study NCT02199964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endura, Refresh artificial tears
Description: Over the counter therapy for dry eye, used 4 times a day
Study NCT01380561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asimadoline
Description: 10mg \[14\]C labelled asimadoline Day 1 then 7 doses 0.5 mg asimadoline bid beginning on Day 2 and ending on Day 5.
Study NCT03099109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3321367
Description: Administered IV
Study NCT03099109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3300054
Description: Administered IV
Study NCT02490631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate cloths
Description: Cleansing twice pre-operatively jawline to toes with 2% chlorhexidine gluconate cloths
Study NCT02877225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib (test treatment) 140 milligram (mg), tablet.
Study NCT02877225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMBRUVICA
Description: IMBRUVICA (reference treatment), 140-mg capsule
Study NCT05475314 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ReFerm(R)
Description: Enemas of approx 250 mL twice daily
Study NCT05475314 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: ReFerm(R)
Description: Enemas of approx 250 mL twice daily
Study NCT04186312 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ACCESS - Accessing Campus Connections & Empowering Student Success
Description: Cognitive-Behavioral Treatment delivered across 2 semesters via group and individual mentoring sessions
Study NCT04186312 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACCESS - Accessing Campus Connections & Empowering Student Success
Description: Cognitive-Behavioral Treatment delivered across 2 semesters via group and individual mentoring sessions
Study NCT00972374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 ug Brimonidine Implant
Description: 400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.
Study NCT03656718 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: (IV) Specified Dose on Specified Days
Study NCT00972374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 ug Brimonidine Implant
Description: 200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.
Study NCT00972374 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham (no implant)
Description: Sham Posterior Segment Drug Delivery system on Day 1 in the study eye.
Study NCT01800747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antibiotic prescription strategies
Description: The patients enrolled will be randomized between three treatment strategies or arms. Patients randomized to delayed treatment arm or direct treatment, doctors can choose the antibiotic that they consider appropriate depending on such local resistance or practice.
Study NCT01800747 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic prescription strategies
Description: The patients enrolled will be randomized between three treatment strategies or arms. Patients randomized to delayed treatment arm or direct treatment, doctors can choose the antibiotic that they consider appropriate depending on such local resistance or practice.
Study NCT02943837 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Device: 22G FNA needle
Study NCT02943837 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Device: 20G FNB needle
Study NCT01454726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaoshi Jifa therapy plus the Western medical treatment.
Description: Diaoshi Jifa treatment
Study NCT02460809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: Transcranial direct current stimulation (tDCS) uses two surface electrodes placed on the scalp. These electrodes pass a low voltage current and modulate membrane potentials of underlying neurons.
Study NCT02460809 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: Transcranial direct current stimulation (tDCS) uses two surface electrodes placed on the scalp. These electrodes pass a low voltage current and modulate membrane potentials of underlying neurons.
Study NCT00669708 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cooling compound (ph5 Eucerin)
Description: application twice daily to the skin
Study NCT00669708 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: cooling compound (ph5 Eucerin)
Description: application twice daily to the skin
Study NCT03353480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Tablet manufactured in China
Description: 250 mg Azithromycin Tablet manufactured in China
Study NCT03353480 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Azithromycin Tablet manufactured in US
Description: 250 mg Azithromycin Tablet manufactured in US
Study NCT03363516 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebral 3 Tesla MRI
Description: Subjects will be examined using a 3 Tesla MR750 GE MRI scanner with an eight-channel head coil. All participants will undergo the same MRI protocol, including: whole-brain 3D T1-weighted spoiled gradient recalled (SPGR) (BRAVO, voxel size of 1 × 1 × 1 mm3), DTI (voxel size 2 × 2 × 2 mm3, 27 directions with gradients at a b-value of 1,000 s/mm2 and 4 b = 0 images) and conventional 2D T2-weighted,T2 (FLAIR) and T2 gradient echo.
Study NCT01412294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine, Cisplatin
Description: Drug: Capecitabine Capecitabine will be administered at 1,000 mg/m2 orally, twice daily (2,000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.~Drug: Cisplatin Cisplatin will be administered at 80 mg/m2 by intravenous infusion on Day 1 of each 21-day treatment cycle.
Study NCT02800317 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RISAS
Description: RISAS procedure contains Radioactive Iodine Seed localisation in the Axilla in axillary node positive breast cancer combined with a Sentinel node procedure.
Study NCT01473602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Administered by SC injection
Study NCT01473602 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by SC injection
Study NCT01473602 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium supplementation
Description: Administered orally
Study NCT01473602 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Description: Administered orally
Study NCT01473602 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D supplementation
Description: Administered orally
Study NCT01473602 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Description: Administered orally
Study NCT02857062 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E45 Eczema Repair Emollient
Description: E45 Eczema Repair Emollient
Study NCT02824042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anetumab ravtansine (BAY94-9343)
Description: Anetumab ravtansine given IV On Day 1 of each 21-day treatment cycle Part 1: Cycle 1 Day 1: 6.5 mg/kg of body weight (BW) Cycle 2 Day 1: 0.6 mg/kg BW Part 2: Cycle 1 Day 1: 6.5 mg/kg BW Cycle 2 Day 1: 6.5 mg/kg BW (planned dose) Continuous treatment: Cycles ≥3 Day 1: 6.5 mg/kg BW once every 3 weeks (Q3W)
Study NCT02824042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole 100 mg oral capsules given by mouth Cycle 1 (Day 18): 200 mg twice daily (BID) (Days 19 - 21): 200 mg once daily (QD) Cycle 2 (Days 1-8): 200 mg QD 12 days in total (Part 1 or Part 2)
Study NCT03814824 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: IRIS (Intelligent real-time image segmentation)
Description: IRIS has the ability to identify and display three specific images features that may correlate with dysplasia that are represented in different color schemes.
Study NCT03814824 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: VLE (Volumetric laser endomicroscopy)
Description: VLE uses infrared light to produce real time high-resolution cross sectional imaging of the esophagus.
Study NCT06199856 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound scan
Description: ultrasound scan
Study NCT02582593 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MedX 1116 Rehab Console
Description: This intervention makes use of transcranially applied near infrared light using light emitting diodes. Near infrared light will be applied to the scalp for a period of 1 hour at each session. A total of six session will be held.
Study NCT02582593 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham MedX 1116 Rehab Console
Description: This intervention makes use of sham transcranially applied near infrared light using light emitting diodes. Light emitting diodes (but not near-infrared light) will be applied to the scalp for a period of 1 hour at each session. A total of six session will be held.
Study NCT01317199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Muscadine Plus Grape Skin Extract
Description: Phase I: Dose escalation starts at 500mg pills given by mouth once daily for 28 days per cycle
Study NCT01317199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose MPX
Description: Randomly-assigned participants receive one capsule of drug (500mg MPX) and seven capsules of placebo composed of pulverized rice, once daily for up to 12 cycles (28 days per cycle).
Study NCT01317199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose MPX
Description: Randomly-assigned participants receive 8 capsules of drug (4000mg MPX) once daily for up to 12 cycles (28 days per cycle).
Study NCT01317199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Randomly-assigned participants receive 8 capsules once daily of placebo composed of pulverized rice for up to 12 cycles (28 days per cycle).
Study NCT02563574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: A type of counseling aimed at reducing consumption of alcohol.
Study NCT02563574 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire assessment
Description: Several different types of questionnaires will be fill out by the participants.
Study NCT02563574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire assessment
Description: Several different types of questionnaires will be fill out by the participants.
Study NCT02563574 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurocognitive assessments
Description: Several different types of neurocognitive assessment will be performed.
Study NCT02563574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocognitive assessments
Description: Several different types of neurocognitive assessment will be performed.
Study NCT02563574 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood specimens
Description: Blood specimens will be used to measure the immunological, virologic, and hepatic status, as well as other biomarkers.
Study NCT02563574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood specimens
Description: Blood specimens will be used to measure the immunological, virologic, and hepatic status, as well as other biomarkers.
Study NCT02070952 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CyberKnife Stereotactic Ablative Body Radiation Therapy
Description: The prescribed planned tumor volume (PTV) dose of 36.25 Gy shall be given in 5 fractions using CyberKnife Hypofractionated Stereotactic Ablative Body Radiation Therapy. PTV will be defined per parameters outlined in the protocol and will at minimum include the entire prostate gland.
Study NCT02209220 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positive airway pressure for the treatment of OSA
Study NCT03273088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: A single dose of etanercept (25mg/0.5ml prefilled syringe) was administered subcutaneously to healthy subjects.
Study NCT03273088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: A single dose of etanercept (25mg/0.5ml prefilled syringe) was administered subcutaneously to healthy subjects.
Study NCT00735748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol per os (Tradonal Odis® orodispersible tablets)
Description: Administration of 1 unit dose of 50 mg tramadol perorally given in 3 unit dosages
Study NCT00735748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol IV (Tradonal® IV)
Description: Administration of tramadol IV given in 3 unit dosage of 35 mg
Study NCT03128801 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Global Stretching Program
Description: Participants will be submitted to a GSP in self-management postures weekly for 40 minutes session conducted by one one physical therapist, certified to use the technique (Stretching Global Active). The GSP will last for a period of 8 weeks. The protocol is based on the study of Lawand et al (2015) who used all postures global therapeutic stretching. The investigators will use six self-management postures in a standardized manner, each of which will last for 10 to 20 minutes.
Study NCT03128801 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stabilization Exercises
Description: The exercise protocol and criteria to increase exercise progression was previously described by Hicks et al (2005). It will be directed by a single therapist one to one session based on specific criteria (being able to maintain muscle contraction eight seconds during 30 repetitions in bilateral exercises or during 20 repetitions for unilateral exercises). Each session will be conducted weekly for 40 minutes.
Study NCT03514823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Description: Inspiratory muscle training (IMT) are breathing exercises used to increase strength and endurance of the respiratory muscles.
Study NCT03514823 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No Inspiratory Muscle Training (IMT)
Description: No inspiratory muscle training.
Study NCT01374516 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live, attenuated, dengue serotype 1, 2, 3, 4 virus
Description: 0.5 mL, Subcutaneous
Study NCT01374516 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: (NaCl) 0.9% solution
Description: 0.5 mL, Subcutaneous
Study NCT03112720 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Blood Patch
Description: A device: 17 gauge Tuohy needle will be placed to the epidural space using the loss of resistance technique. Once positioned a sterile stylet will be replaced within the needle to maintain the sterility of the epidural space. A tourniquet may be used to identify a peripheral venous site, which will be sterilely prepped with betadine x3 and then chloraprep. Venipuncture will be performed with a device: 20gauge or larger needle. 20mL of blood will be aspirated in a sterile system into an appropriately sized syringe. After sterile transfer, this autologous blood will be slowly injected into the epidural space.
Study NCT03112720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sphenopalatine Ganglion Block
Description: The drug: 5% lidocaine ointment, a local anesthetic, will be applied to the end of a device: long channeled cotton tipped applicator inserted into both nares and placed over the mucosa in the area of posterior aspect of the middle ethmoid, toward the presumed anatomic location of the sphenopalatine ganglion, evidenced by a slight resistance at the appropriate depth. 5mL of drug: 1% lidocaine solution will then be injected into the hollow shaft of the device: applicator and allowed to topically anesthetize the ganglion by gravity flow for 30 minutes.
Study NCT03359499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacillus clausii
Description: Oral suspension administered BID
Study NCT03359499 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Trimebutine
Description: One tablet of 200 mg of trimebutine administered BID
Study NCT02125084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Study NCT02125084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Study NCT05059509 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FB825
Description: FB825, 5mg/kg, by 1 hour IV infusion on Day 1